Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck, Tony S.K. Mok, Makoto Nishio et al. · The Lancet Respiratory Medicine · 2019
Cited by 946 works. doi:10.1016/s2213-2600(19)30084-0
Authors
- Martin Reck
- Tony S.K. Mok
- Makoto Nishio
- Robert M. Jotte
- Federico Cappuzzo
- Francesco Orlandi
- Daniil Stroyakovskiy
- Naoyuki Nogami
- Delvys Rodríguez‐Abreu
- Denis Moro‐Sibilot
- Christian A. Thomas
- Fabrice Barlési
- Yu Lin Deng
- Marcin Kowanetz
- Geetha Shankar
- Wei Yu Lin
References
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer